ERBB2 and breast carcinoma: These antibodies include the anti-CD20 monoclonal antibody (mAb) for lymphoma, anti-HER2/neu mAb (trastuzumab) for breast cancer, anti-EGFR mAb (panitumumab) for colorectal carcinoma (CRC), anti-VEGF mAb (bevacizumab) for non-small cell lung cancer (NSCLC), malignant gliomas, and renal cancer, anti-CTLA4 mAb (ipilimumab) for melanoma, anti-CD52 mAb (alemtuzumab) for chronic lymphocytic leukemia (CLL), anti-CD30 mAb (brentuximab vedotin) for Hodgkin's lymphoma, and anti-CD33 mAb (Mylotarg) for acute myeloid leukemia (AML) [11–13].